These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17563732)

  • 41. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
    de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
    Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy.
    Kumar S; Lacy MQ; Dispenzieri A; Rajkumar SV; Fonseca R; Geyer S; Allmer C; Witzig TE; Lust JA; Greipp PR; Kyle RA; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2004 Jul; 34(2):161-7. PubMed ID: 15133489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
    Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
    Chaudhury S; Auerbach AD; Kernan NA; Small TN; Prockop SE; Scaradavou A; Heller G; Wolden S; O'Reilly RJ; Boulad F
    Br J Haematol; 2008 Mar; 140(6):644-55. PubMed ID: 18302713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Bone Marrow Transplant; 2009 May; 43(10):779-85. PubMed ID: 19079315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
    Kröger N; Badbaran A; Lioznov M; Schwarz S; Zeschke S; Hildebrand Y; Ayuk F; Atanackovic D; Schilling G; Zabelina T; Bacher U; Klyuchnikov E; Shimoni A; Nagler A; Corradini P; Fehse B; Zander A
    Exp Hematol; 2009 Jul; 37(7):791-8. PubMed ID: 19487069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
    Kothari S; Artz AS; Lee SM; Fulton N; Park JH; Stock W; Larson RA; Odenike O; Kline J; LaBelle J; Kosuri S; Riedell P; Nakamura Y; Bishop MR; Liu H
    Bone Marrow Transplant; 2020 Jun; 55(6):1161-1168. PubMed ID: 31992847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
    Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
    Mohty M; Attal M; Marit G; Bulabois CE; Garban F; Gratecos N; Rio B; Vernant JP; Sotto JJ; Cahn JY; Blaise D; Jouet JP; Facon T; Yakoub-Agha I
    Bone Marrow Transplant; 2005 Jan; 35(2):165-9. PubMed ID: 15531895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
    Minnema MC; van de Donk NW; Zweegman S; Hegenbart U; Schonland S; Raymakers R; Zijlmans JM; Kersten MJ; Bos GM; Lokhorst HM
    Bone Marrow Transplant; 2008 May; 41(9):779-84. PubMed ID: 18195681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
    Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
    Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma.
    Toubai T; Hirate D; Shono Y; Ota S; Ibata M; Mashiko S; Sugita J; Shigematsu A; Miura Y; Kato N; Umehara S; Kahata K; Tsutsumi Y; Iwao N; Toyoshima N; Tanaka J; Asaka M; Imamura M
    Int J Lab Hematol; 2008 Feb; 30(1):75-81. PubMed ID: 18190473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation.
    Yoshimi A; Izutsu K; Takahashi M; Kako S; Oshima K; Kanda Y; Motokura T; Chiba S; Momose T; Ohtomo K; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):477-81. PubMed ID: 18266206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.